Falcon Wealth Planning Acquires 158 Shares of Johnson & Johnson (NYSE:JNJ)

Falcon Wealth Planning raised its holdings in Johnson & Johnson (NYSE:JNJ) by 5.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 2,852 shares of the company’s stock after buying an additional 158 shares during the period. Falcon Wealth Planning’s holdings in Johnson & Johnson were worth $462,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. bought a new position in shares of Johnson & Johnson during the 1st quarter worth $765,000. Pullen Investment Management LLC bought a new position in shares of Johnson & Johnson during the 1st quarter worth $1,166,000. Argent Advisors Inc. grew its position in shares of Johnson & Johnson by 3.2% during the 1st quarter. Argent Advisors Inc. now owns 15,468 shares of the company’s stock worth $2,447,000 after buying an additional 476 shares in the last quarter. PDS Planning Inc grew its position in shares of Johnson & Johnson by 2.4% during the 1st quarter. PDS Planning Inc now owns 15,119 shares of the company’s stock worth $2,392,000 after buying an additional 353 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. grew its position in shares of Johnson & Johnson by 140.0% during the 1st quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company’s stock worth $3,986,000 after buying an additional 14,700 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on JNJ shares. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Morgan Stanley upped their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Sanford C. Bernstein upped their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Finally, TD Cowen decreased their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $175.93.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

Johnson & Johnson stock opened at $158.35 on Wednesday. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The stock has a market cap of $381.25 billion, a PE ratio of 22.92, a price-to-earnings-growth ratio of 2.84 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The stock has a 50-day moving average of $163.09 and a two-hundred day moving average of $155.75.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period last year, the business posted $2.66 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.13%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.